[go: up one dir, main page]

WO1998013501A3 - Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales - Google Patents

Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales Download PDF

Info

Publication number
WO1998013501A3
WO1998013501A3 PCT/US1997/016718 US9716718W WO9813501A3 WO 1998013501 A3 WO1998013501 A3 WO 1998013501A3 US 9716718 W US9716718 W US 9716718W WO 9813501 A3 WO9813501 A3 WO 9813501A3
Authority
WO
WIPO (PCT)
Prior art keywords
viruses
promoter region
polymerase gene
attenuation
genomic promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/016718
Other languages
English (en)
Other versions
WO1998013501A2 (fr
Inventor
Mohinderjit S Sidhu
Stephen A Udem
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
US Department of Health and Human Services
Original Assignee
American Cyanamid Co
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, US Department of Health and Human Services filed Critical American Cyanamid Co
Priority to BR9712138-0A priority Critical patent/BR9712138A/pt
Priority to EP97942613A priority patent/EP0932684A2/fr
Priority to JP10515749A priority patent/JP2000517194A/ja
Priority to AU44278/97A priority patent/AU4427897A/en
Priority to CA002265554A priority patent/CA2265554A1/fr
Publication of WO1998013501A2 publication Critical patent/WO1998013501A2/fr
Publication of WO1998013501A3 publication Critical patent/WO1998013501A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des virus d'ARN de l'ordre des Mononegavirales qui sont isolés, produits par recombinaison, atténués, non segmentés, à sens négatif et monocaténaires, et qui présentent au moins une mutation d'atténuation dans la région promotrice 3' du génome et au moins une mutation d'atténuation dans le gène polymérase de l'ARN. On formule des vaccins avec ces virus et un support physiologiquement acceptable. Ces vaccins permettent d'immuniser un individu par induction d'une protection contre un virus monocaténaire, non segmenté et à sens négatif de l'ordre des Mononegavirales.
PCT/US1997/016718 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales Ceased WO1998013501A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BR9712138-0A BR9712138A (pt) 1996-09-27 1997-09-19 Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
EP97942613A EP0932684A2 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
JP10515749A JP2000517194A (ja) 1996-09-27 1997-09-19 モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
AU44278/97A AU4427897A (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
CA002265554A CA2265554A1 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2682396P 1996-09-27 1996-09-27
US60/026,823 1996-09-27

Publications (2)

Publication Number Publication Date
WO1998013501A2 WO1998013501A2 (fr) 1998-04-02
WO1998013501A3 true WO1998013501A3 (fr) 1998-08-13

Family

ID=21833976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016718 Ceased WO1998013501A2 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales

Country Status (8)

Country Link
EP (1) EP0932684A2 (fr)
JP (1) JP2000517194A (fr)
KR (1) KR20000048628A (fr)
CN (1) CN1232504A (fr)
AU (1) AU4427897A (fr)
BR (1) BR9712138A (fr)
CA (1) CA2265554A1 (fr)
WO (1) WO1998013501A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
JP2001517448A (ja) * 1997-09-19 2001-10-09 アメリカン・サイアナミド・カンパニー 弱毒化呼吸合胞体ウイルス
IL138681A0 (en) * 1998-03-26 2001-10-31 American Cyanamid Co Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
EP1090108B1 (fr) * 1998-06-03 2011-02-23 Wyeth Holdings Corporation Nouveau procede pour recuperer des virus a arn
WO1999064570A1 (fr) 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Nouveaux procedes et substrats deficients en interferon pour la propagation de virus
ATE384126T1 (de) 1998-06-12 2008-02-15 Sinai School Medicine Interferon induzierende genetisch veränderte attenuierte viren
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US6635416B2 (en) 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
IL153004A0 (en) * 2000-06-23 2003-06-24 American Cyanamid Co Modified morbillivirus v proteins
US7361496B1 (en) 2000-08-02 2008-04-22 Wyeth Rescue of mumps virus from cDNA
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US8927206B2 (en) 2001-01-19 2015-01-06 Vironovative B.V. Virus causing respiratory tract illness in susceptible mammals
TWI359868B (en) 2002-02-21 2012-03-11 Medimmune Vaccines Inc Recombinant parainflulenza virus expression system
ES2526191T3 (es) 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1375670B1 (fr) 2002-06-20 2013-06-12 Institut Pasteur Virus de la rougeole recombinants exprimant des épitopes d' antigènes de virus à ARN et utilisation des virus recombinants pour la préparation de vaccins
EP2110382A1 (fr) * 2002-06-20 2009-10-21 Institut Pasteur ADNc infectieux pour une souche de vaccin améliorée du virus de la rougeole Utilisation pour compositions immunogènes
CA2432738A1 (fr) * 2003-02-26 2004-08-26 Philippe Despres Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques
ATE469170T1 (de) 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
AU2004235347B2 (en) 2003-04-25 2010-09-16 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
CA2816222A1 (fr) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Hemagglutinine du virus de la grippe et variantes de la neuraminidase
EP1697521B1 (fr) 2003-12-23 2010-06-02 MedImmune, LLC Systeme a plasmides multiples pour la production du virus de la grippe
CA2822895A1 (fr) 2004-05-25 2005-12-08 Medimmune, Llc Variantes hemagglutinine et neuraminidase de la grippe
WO2006083286A2 (fr) 2004-06-01 2006-08-10 Mount Sinai School Of Medicine Of New York University Virus de la grippe porcine genetiquement modifie et ses applications
EP1855713B1 (fr) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Virus de la grippe équine génétiquement modifié et utilisations associées
EP2441471B1 (fr) 2005-03-08 2014-10-08 MedImmune, LLC Virus de la grippe réassortis
WO2007002008A2 (fr) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Procedes et compositions permettant d'exprimer un virus a arn sens negatif dans des cellules canines
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CN101365479B (zh) 2005-12-02 2013-06-26 纽约大学西奈山医学院 呈现非天然表面蛋白的嵌合病毒及其应用
ES2539514T3 (es) 2006-04-19 2015-07-01 Medimmune, Llc Métodos y composiciones para expresar ARN viral de sentido negativo en células de canino
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
EP2056872A4 (fr) 2006-08-09 2016-12-21 Medimmune Llc Variants d'hémagglutinine et de neuraminidase de la grippe
AU2007353532A1 (en) * 2006-12-22 2008-11-20 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof
ES2523587T3 (es) 2007-06-18 2014-11-27 Medimmune, Llc Virus influenza B que tienen alteraciones en el polipéptido hemaglutinina
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
EP2356135B1 (fr) 2008-11-05 2017-10-25 Wyeth LLC Composition immunogène à multiples composants pour la prévention d'une maladie streptococcique bêta-hémolytique (bhs)
WO2010091262A1 (fr) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Virus chimériques de la maladie de newcastle et leurs utilisations
WO2010093537A2 (fr) 2009-02-12 2010-08-19 Medimmune, Llc Hémagglutinine du virus de la grippe et variants de la neuraminidase
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
EP2459585B1 (fr) 2009-07-30 2024-09-04 Icahn School of Medicine at Mount Sinai Virus de la grippe et leurs utilisations
WO2011123495A1 (fr) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Vaccins contre le virus de la grippe et utilisations associées
EP2420242A1 (fr) 2010-08-20 2012-02-22 Lauer, Ulrich M. Virus de la rougeole oncolytique
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
CA2838614A1 (fr) 2011-06-08 2013-04-04 Vishwas Joshi Systeme d'expression simple de mammifere a deux plasmides destine a la production de proteines et de virus recombines
CN104185476A (zh) 2011-09-20 2014-12-03 西奈山医学院 流感病毒疫苗及其应用
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EA038981B1 (ru) 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
CA2940570A1 (fr) 2014-02-27 2015-09-03 Viralytics Limited Therapie combinee pour le traitement du cancer
CA2974699A1 (fr) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Regimes de vaccination contre le virus de la grippe
MX2017010908A (es) 2015-02-26 2017-12-07 Boehringer Ingelheim Vetmedica Gmbh Vacuna bivalente contra el virus de gripe porcina.
CN116196403A (zh) 2015-08-03 2023-06-02 美国卫生和人力服务部 Brachyury缺失突变体、编码该缺失突变体的非酵母载体及其用途
AU2016308917A1 (en) 2015-08-20 2018-03-15 Cornell University Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
WO2017031408A1 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus à cycle unique pour le développement de vaccins contre la grippe canine
US10973903B2 (en) 2015-08-20 2021-04-13 University Of Rochester NS1 truncated virus for the development of canine influenza vaccines
EP3463439B1 (fr) 2016-06-03 2022-08-03 University of Rochester Vaccins vivants atténués contre le virus de la grippe équine
CA3023143A1 (fr) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Hemagglutinines du virus de la grippe et utilisations de celles-ci
WO2018187706A2 (fr) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3087239A1 (fr) 2018-02-27 2019-09-06 University Of Rochester Vaccin vivant attenue multivalent contre la grippe pour la prevention et le controle du virus de la grippe equine (eiv) chez les chevaux
CA3104297A1 (fr) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Polypeptides d'hemagglutinines du virus de la grippe en mosaique et leurs utilisations
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
CN113905759A (zh) 2019-02-27 2022-01-07 罗切斯特大学 用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗
US11103576B1 (en) 2020-06-15 2021-08-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Measles virus vaccine expressing SARS-COV-2 protein(s)
WO2025019631A1 (fr) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Compositions immunogènes contenant un virus de la grippe a inactivé et un adjuvant oligonucléotidique cpg et leurs utilisations
WO2025080985A1 (fr) 2023-10-13 2025-04-17 Flagship Pioneering Innovations V, Inc. Distribution d'anellovecteur spécifique à un tissu
WO2025160409A1 (fr) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Vecteurs viraux pour moduler la fonction vegf

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (fr) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN ADNc correspondant au génome des virus à ARN "brin-négatifs" et procédé pour la production de virus à ARN "brin-négatifs" infectieux
EP0540135A2 (fr) * 1991-10-14 1993-05-05 The Kitasato Institute Souche attenuée vaccinale du virus de la rougeole, contenant une séquence nucléotidique spécifique et procédé pour son identification absolue
EP0567100A1 (fr) * 1992-04-21 1993-10-27 American Cyanamid Company Virus syncytial respiratoire (RSV) mutant, vaccins le contenant et méthodes d'utilisation
WO1993021306A1 (fr) * 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Virus attenues par genie genetique
WO1993021310A1 (fr) * 1992-04-21 1993-10-28 American Home Products Corporation Compositions de vaccins a base de virus respiratoire syncytial attenue
EP0702085A1 (fr) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Virus ARN récombinant, infectieux, non-segmenté, brin-négatif

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (fr) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN ADNc correspondant au génome des virus à ARN "brin-négatifs" et procédé pour la production de virus à ARN "brin-négatifs" infectieux
EP0540135A2 (fr) * 1991-10-14 1993-05-05 The Kitasato Institute Souche attenuée vaccinale du virus de la rougeole, contenant une séquence nucléotidique spécifique et procédé pour son identification absolue
WO1993021306A1 (fr) * 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Virus attenues par genie genetique
EP0567100A1 (fr) * 1992-04-21 1993-10-27 American Cyanamid Company Virus syncytial respiratoire (RSV) mutant, vaccins le contenant et méthodes d'utilisation
WO1993021310A1 (fr) * 1992-04-21 1993-10-28 American Home Products Corporation Compositions de vaccins a base de virus respiratoire syncytial attenue
EP0702085A1 (fr) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Virus ARN récombinant, infectieux, non-segmenté, brin-négatif

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLLINS P.L. ET AL.: "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.", PROC. NATL. ACAD. SCI. USA, vol. 92, December 1995 (1995-12-01), pages 11563 - 11567, XP002066592 *
CROWE J.E. ET AL.: "Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.", VIRUS GENES, vol. 13, no. 3, February 1996 (1996-02-01), pages 269 - 273, XP002066591 *
MORI T. ET AL.: "Molecular cloning and complete nucleotide sequence of genomic RNA of the AIK-C strain of attenuated measles virus.", VIRUS GENES, vol. 7, no. 1, 1993, pages 67 - 81, XP002051752 *
RADECKE F. ET AL.: "RESCUE OF MEASLES VIRUSES FROM CLONED DNA", EMBO JOURNAL, vol. 14, no. 23, 1 December 1995 (1995-12-01), pages 5773 - 5784, XP002022952 *
STOKES A. ET AL.: "The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses(cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3).", VIRUS RESEARCH, vol. 30, 1993, pages 43 - 52, XP002051711 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Also Published As

Publication number Publication date
BR9712138A (pt) 2000-01-18
JP2000517194A (ja) 2000-12-26
KR20000048628A (ko) 2000-07-25
CN1232504A (zh) 1999-10-20
AU4427897A (en) 1998-04-17
CA2265554A1 (fr) 1998-04-02
WO1998013501A2 (fr) 1998-04-02
EP0932684A2 (fr) 1999-08-04

Similar Documents

Publication Publication Date Title
WO1998013501A3 (fr) Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
WO1995012660A3 (fr) Procedes et compositions relatifs a l'adenovirus p53 recombine
CA2011878A1 (fr) Regions immunogenes sur la proteine e7 du papillomavirus humain de type 16
EP1128832A4 (fr) Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees
WO2004014314A3 (fr) Procedes et compositions concernant les poxvirus et le cancer
WO1995032298A3 (fr) Vecteurs surs pour therapie genique
WO2001068103A3 (fr) Methode pouvant ameliorer les symptomes d'une infection herpetique au moyen de sequences polynucleotidiques immunomodulatrices
WO1999029717A3 (fr) Virus porcins du syndrome de deperissement multisystemique apres sevrage
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2186044A1 (fr) Nouveaux virus mutes, composes antiviraux et nouveaux procedes de production de vaccins
CA2113089A1 (fr) Cellules donneuses universelles
GB9306731D0 (en) Vaccines
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
CA2329510A1 (fr) Sequences de type promoteur exprimees dans les antheres et les pollens
WO2001077358A3 (fr) Virus de l'herpes destines a l'immunomodulation
AU4425397A (en) Antisense gene therapy for rna viruses
WO1999049017A3 (fr) Mutations responsables de l'attenuation du virus de la rougeole ou du virus respiratoire syncytial humain du sous-groupe b
CA2066998A1 (fr) Virus de la varicella-zona recombinant et procede de construction
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97198321.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997942613

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2265554

Country of ref document: CA

Ref document number: 2265554

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09269367

Country of ref document: US

ENP Entry into the national phase

Ref document number: 1998 515749

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997002569

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997942613

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997002569

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997942613

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997002569

Country of ref document: KR